in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Merck KGaA appoints Simon Sturge as new head of biosimilars unit
3:27 AM MST | February 20, 2014 | Deepti Ramesh
Merck KGaA says that Simon Sturge will join the company from Boehringer Ingelheim (Ingelheim, Germany) effective 1 March 2014, to head the biosimilars unit. The Simon Sturge. biosimilars unit is part of Merck’s pharmaceutical businesses alongside with Merck Serono (Darmstadt, Germany), the consumer health division and the Allergopharma unit. Sturge, in his new role, will report to Stefan Oschmann, member of Merck’s executive board and responsible for the company’s pharmaceutical businesses. Sturge succeeds Thierry Hulot, who created the...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee